Published in Arch Neurol on April 01, 1997
The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry (1999) 3.98
Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology (2010) 2.74
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci (2009) 2.38
Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci (2008) 2.34
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther (2008) 2.29
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A (2003) 1.96
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol (2006) 1.94
Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A (2009) 1.87
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A (2008) 1.86
Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol (2008) 1.68
Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci U S A (1998) 1.61
A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci (2009) 1.57
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci (2010) 1.52
Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology (2009) 1.45
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation. Brain Behav Immun (2014) 1.44
Cholinergic effects on fear conditioning II: nicotinic and muscarinic modulations of atropine-induced disruption of the degraded contingency effect. Psychopharmacology (Berl) (2005) 1.43
Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology (2011) 1.42
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) (2004) 1.42
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol (2008) 1.32
Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Neuropsychopharmacology (2014) 1.25
Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. ACS Chem Neurosci (2013) 1.24
Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) (2004) 1.22
Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease. ACS Chem Neurosci (2012) 1.22
Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis (2013) 1.20
Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bioorg Med Chem Lett (2008) 1.15
Quinolizidinone carboxylic acids as CNS penetrant, selective m1 allosteric muscarinic receptor modulators. ACS Med Chem Lett (2010) 1.13
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. J Neurosci (2012) 1.13
Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. Bioorg Med Chem Lett (2012) 1.10
Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev (2013) 1.08
Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol (2010) 1.07
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci (2014) 1.06
Targeting glutamate synapses in schizophrenia. Trends Mol Med (2011) 1.06
Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol Biosyst (2010) 1.01
Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Bioorg Med Chem Lett (2008) 1.01
Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169. ACS Chem Neurosci (2012) 1.01
Neural circuitry and immunity. Immunol Res (2015) 0.97
Allosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophrenia. Neuropsychopharmacology (2010) 0.94
Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Neuron (2016) 0.90
Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice. Psychopharmacology (Berl) (2009) 0.90
Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. Drug Discov Today (2013) 0.90
Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature (2016) 0.90
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorg Med Chem Lett (2011) 0.89
Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuropsychopharmacology (2013) 0.88
Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl) (2008) 0.87
Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. Discov Med (2012) 0.86
Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl) (2008) 0.86
Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism. Bioorg Med Chem Lett (2012) 0.85
Role of the central cholinergic system in the therapeutics of schizophrenia. Curr Neuropharmacol (2008) 0.84
Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. ACS Med Chem Lett (2016) 0.83
Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence? Front Psychiatry (2013) 0.82
The biochemical womb of schizophrenia: A review. Indian J Clin Biochem (2008) 0.82
Identification of amides as carboxylic Acid surrogates for quinolizidinone-based m1 positive allosteric modulators. ACS Med Chem Lett (2012) 0.82
Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](+)3-MPB and scopolamine in conscious monkeys. Neuropsychopharmacology (2011) 0.81
Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats. Psychopharmacology (Berl) (2013) 0.80
Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. Psychopharmacology (Berl) (2014) 0.80
Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. Bioorg Med Chem Lett (2014) 0.80
M1 muscarinic receptor for the development of auditory cortical function. Mol Brain (2010) 0.79
Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor. J Biol Chem (2014) 0.79
The Effects of Methylphenidate on Resting-State Functional Connectivity of the Basal Nucleus of Meynert, Locus Coeruleus, and Ventral Tegmental Area in Healthy Adults. Front Hum Neurosci (2016) 0.78
Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil. Psychiatry Investig (2016) 0.78
Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations. Neuropsychopharmacology (2015) 0.78
Alzheimer's disease: Targeting the Cholinergic System. Curr Neuropharmacol (2016) 0.78
G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs. Front Aging Neurosci (2016) 0.78
Malignant synaptic growth and Alzheimer's disease. Future Neurol (2012) 0.77
Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. J Chem Neuroanat (2010) 0.77
Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function. Pharmacol Rep (2014) 0.77
Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis. Psychopharmacology (Berl) (2008) 0.77
Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256. ACS Chem Neurosci (2016) 0.77
Effect of cholinergic signaling on neuronal cell bioenergetics. J Alzheimers Dis (2013) 0.76
Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Bioorg Med Chem Lett (2016) 0.76
Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates. PLoS One (2015) 0.76
An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M 1) positive allosteric modulator in the living human brain using positron emission tomography. EJNMMI Res (2014) 0.76
Why an M1 Antagonist Could Be a More Selective Model for Memory Impairment than Scopolamine. Front Neurol (2016) 0.75
Prediction of consensus binding mode geometries for related chemical series of positive allosteric modulators of adenosine and muscarinic acetylcholine receptors. J Comput Chem (2017) 0.75
3-[3-(3-florophenyl-2-propyn-1-ylthio)-1, 2, 5-thiadiazol-4-yl]-1, 2, 5, 6-tetrahydro-1- methylpyridine oxalate, a novel xanomeline derivative, improves neural cells proliferation and survival in adult mice. Neural Regen Res (2012) 0.75
Discovery of novel N-substituted oxindoles as selective m1 and m4 muscarinic acetylcholine receptors partial agonists. ACS Med Chem Lett (2013) 0.75
Role of Cholinesterase Inhibitors in Managing Behavioral Problems in Alzheimer's Disease. Prim Care Companion J Clin Psychiatry (2004) 0.75
M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. J Clin Invest (2016) 0.75
Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease. Curr Neuropharmacol (2017) 0.75
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects. Neuropharmacology (2015) 0.75
[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors. EJNMMI Res (2013) 0.75
Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. Front Pharmacol (2016) 0.75
Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders. Neuron (2017) 0.75
Protection from interferon-β-induced neuronal apoptosis through stimulation of muscarinic acetylcholine receptors coupled to ERK1/2 activation. Br J Pharmacol (2016) 0.75
Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors. PLoS One (2014) 0.75
Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease. J Neural Transm (Vienna) (2016) 0.75
Acetylcholine modulates gamma frequency oscillations in the hippocampus by activation of muscarinic M1 receptors. Eur J Neurosci (2017) 0.75
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron (1996) 5.30
Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther (1973) 5.23
Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 5.14
Localization of neuronal and glial glutamate transporters. Neuron (1994) 5.14
Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science (1986) 4.44
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther (1973) 4.40
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.07
Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther (1973) 3.89
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med (1992) 3.87
Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol (1995) 3.66
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol (1997) 3.62
Preclinical prediction of Alzheimer's disease using SPECT. Neurology (1998) 3.60
Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry (1995) 3.30
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis (1997) 3.29
Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience (1983) 3.26
Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med (1996) 3.23
Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol (1983) 3.19
Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum (2001) 3.14
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum (1998) 2.92
Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci (1998) 2.81
Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol (2001) 2.68
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry (2000) 2.66
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol (1991) 2.54
Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci U S A (1991) 2.50
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry (1999) 2.46
Neurosteroids act on recombinant human GABAA receptors. Neuron (1990) 2.44
Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (1999) 2.43
The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. J Nucl Med (1992) 2.39
Binding of syndecan-like cell surface proteoglycan receptors is required for Neisseria gonorrhoeae entry into human mucosal cells. EMBO J (1995) 2.37
Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. J Neurosci (1985) 2.37
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry (2000) 2.34
Prevalence of left ventricular hypertrophy in a general population; The Tromsø Study. Eur Heart J (1999) 2.32
Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med (1996) 2.27
The dysarthria-clumsy hand syndrome: a distinct clinical entity related to pontine infarction. Ann Neurol (1990) 2.25
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv (1997) 2.21
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest (1999) 2.21
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol (2000) 2.21
Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA (1998) 2.20
Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A (1996) 2.18
Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc Natl Acad Sci U S A (1997) 2.10
Nizatidine versus placebo in gastro-oesophageal reflux disease: a 12-week, multicentre, randomised, double-blind study. Br J Clin Pract Suppl (1994) 2.09
A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol (1992) 2.05
A novel augmentation strategy for treating resistant major depression. Am J Psychiatry (2001) 2.05
Percutaneous transluminal coronary angioplasty versus thrombolysis in acute myocardial infarction. Scand Cardiovasc J (2000) 2.03
Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci U S A (1998) 2.00
Intracellular studies in the facial nucleus illustrating a simple new method for obtaining viable motoneurons in adult rat brain slices. Synapse (1989) 1.99
Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci (1994) 1.98
MLC typing in juvenile diabetes mellitus and idiopathic Addison's disease. Transplant Rev (1975) 1.97
A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci (1974) 1.93
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry (2000) 1.93
Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci (1995) 1.92
Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci (1995) 1.91
Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther (1973) 1.90
Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci U S A (1990) 1.90
The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci (1995) 1.89
Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts. Nucleic Acids Res (1995) 1.89
Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci (2000) 1.88
Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron (2001) 1.87
Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.87
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A (2008) 1.86
Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med (1997) 1.86
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol (1997) 1.82
Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study Group. Am J Gastroenterol (1989) 1.79
Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology (2000) 1.76
Receptors for the age of anxiety: pharmacology of the benzodiazepines. Science (1980) 1.76
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther (1975) 1.75
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology (1974) 1.70
Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci (2000) 1.69
Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience (1995) 1.68
AMPA glutamate receptor subunits are differentially distributed in rat brain. Neuroscience (1993) 1.66
The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res (2000) 1.64
Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet (2001) 1.63
High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem (1991) 1.62
A randomized trial of exercise and dietary counseling after liver transplantation. Am J Transplant (2006) 1.61
Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci U S A (1998) 1.61
D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. Proc Natl Acad Sci U S A (1994) 1.60
Mitral flow derived Doppler indices of left ventricular diastolic function in a general population; the Tromso study. Eur Heart J (2000) 1.58
Biochemical characterization and localization of a non-N-methyl-D-aspartate glutamate receptor in rat brain. J Neurochem (1992) 1.58
A genome-wide search for chromosomal loci linked to bipolar affective disorder in the Old Order Amish. Nat Genet (1996) 1.56
D1 and D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci U S A (1991) 1.55
Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol (1999) 1.55
Serum cobalamin, homocysteine, and methylmalonic acid concentrations in a multiethnic elderly population: ethnic and sex differences in cobalamin and metabolite abnormalities. Am J Clin Nutr (1999) 1.55
Mapping quantitative trait loci for open-field behavior in mice. Behav Genet (1997) 1.54
Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. Arch Gen Psychiatry (1988) 1.53
Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. Am J Kidney Dis (2000) 1.53
A selective imidazobenzodiazepine antagonist of ethanol in the rat. Science (1986) 1.53
Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett (1996) 1.52
Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem (2000) 1.52
Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia (2001) 1.52
Positron emission tomography in Alzheimer's disease. Neurology (1986) 1.52
Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol (1997) 1.50